期刊文献+

英夫利昔单抗治疗类风湿关节炎药物经济学研究概述 被引量:3

下载PDF
导出
摘要 类风湿关节炎(rheumatoid arthritis,RA)是一种表现为关节肿胀、疼痛和炎症症状的全身性慢性疾病。北美RA的患病率估计为0.5%~1.0%,每年大约导致美国900万人次求医和超过25万人次住院。女性发病率更高,约占2/3,发病年龄多在40~70岁,病人损失的是劳动生产率最高的生命时间,因此间接成本较高。
作者 李洪超 董鹏
出处 《临床药物治疗杂志》 2008年第4期23-27,共5页 Clinical Medication Journal
  • 相关文献

参考文献21

  • 1[1]Quan V,Doan,Chiun-Fang Chiou,Robert W,Dubois.Review of Eight Pharmacoeconomic Studios of the Value of Biologic DMARDs(Adalimumab,Etancrcept,and Infliximab) in the Management of Rheumatoid Arthritis.Journal of Managed Care Pharmacy,2006,12(7):555-569
  • 2[2]Michael T,Nurmohamed,Ben A.C,Dijkmans.Efficacy,Tolerability and Cost Effectiveness of Diaease-Medifying Antirheumatic Drugs and Biologic Agents in Rheumatoid Arthritis.Drugs,2005,65(5):661-694
  • 3[3]Lee DM,Weinblatt ME.Rheumatoid arthritis.Lancet,2001,358:903-11
  • 4[4]Ledingham J,Deighton C.Update on the British Society for Rhcumatology guidelines for prescribing TNF alpha blockers in adults with rheumatoid arthritis(update of previous guidelines of April 2001).Rheumatolngy.(Oxford),2005,44(2):157-63
  • 5[5]Cooper NJ.Economic burden of rheumatoid arthritis:a systematic review.Rheumatology,2000,39:28-33
  • 6[6]Anne-Christine Rat,Marie-Christuphe Boissier.Rheumatoid arthritis:direct and indirect costs.Joint Bone Spine,2004,(71):518-524
  • 7史方,顾凯,卢伟,翁伟芳,朱美英,彭艳英,傅东波,朱建林,傅华.上海市关节炎疾病经济负担评价[J].中国卫生资源,2007,10(2):92-94. 被引量:6
  • 8[9]Marco Barbieri,John B.Wong,Michael Drummond.The Cost Effectiveness of Infliximab for Severe Treatment-Resistant Rheumatoid Arthritis in the UK.Pharmacoeconomics,2005,23(6):607-618
  • 9[10]American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines.Guidelines for the management of rheumatoid arthritis:2002 update.Arthritis Rheum,2002,46(2):328-346
  • 10[11]Felson DT,Anderson JJ,Boers M,et al.Ameriean College of Rheumatology.Preliminary definition of improvement in rheumatoid arthritis.Arthritis Rheum,1995,38(6):727-735

二级参考文献9

  • 1魏颖,杜乐勋.附录B测定疾病经济负担的方法[M].卫生经济学与卫生经济管理,北京:人民卫生出版社,1998.432-444.
  • 2Fautrel, -B, Guillemin,-F. Cost of illness studies in rheumatic diseases [ J ]. Curr-Opin-Rheumatol,2002,14 ( 2 ) : 121-126.
  • 3江启成,李绍华.第十二章疾病经济负担,卫生经济学教程[M].合肥:安徽科学技术出版社,2002.145—158.
  • 4Cooper-N-J. Economic burden of rheumatoid arthritis:a systematic review[ J]. Rheumatology-(Oxford) ,2000,39 ( 1 ) :28-33.
  • 5Woo, -J, Lau, -E, Lau, -C-S, et al. Socioeconomic impact of ostooarthritis in Hong Kong:utilization of health and social services,and direct and indirect costs[ J ]. Arthritis-Rheum ,2003,49 ( 4 ) :526-534.
  • 6Zink,-A, Huscher, -D, Westhoff,-G. Versorgungsforschung im Kompetenznetz Rheuma-Was leistet sie fur die Verbesserung der Versorgung? ( Research in patient care in the rheumatology specialty network-what is the benefit for improving patient care?) [ J]. Z-Rheumatol,2002,61 ( 1 ) :3-12.
  • 7Tijhuis, -G-J, Zwinderman, -A-H, Hazes, -J-M, et al. Two-year follow-up of a randomized controlled trial of a clinical nurse specialist intervention,inpatient ,and day patient team care in rheumatlil arthritis[ J]. J-Adv-Nurs ,2003,41 (1):34-43.
  • 8李顺平,袁方曙.疾病的经济损失及其衡量[J].卫生经济研究,1998,15(10):10-11. 被引量:10
  • 9史方,顾凯,卢伟,翁伟芳,朱美英,彭艳英,傅东波,傅华.上海市关节炎患病率抽样调查及相关因素分析[J].中华流行病学杂志,2003,24(12):1136-1140. 被引量:26

共引文献5

同被引文献13

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部